FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide. PMID 40556483 · Clin Pharmacol Ther · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection. PMID 40552763 · Gut Microbes · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up. PMID 40537903 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effects of music therapy on pain and anxiety in young nulliparous patients undergoing laparoscopic cystectomy for endometriosis: a randomized controlled trial. PMID 40534482 · J Psychosom Obstet Gynaecol · 2025-Dec 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial. PMID 40509553 · Eur Stroke J · 2025-Dec 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in esophageal adenocarcinoma tumors: A randomized controlled trial. PMID 40499717 · J Sport Health Sci · 2025-Dec The study is a randomized controlled trial in human esophageal adenocarcinoma with a drug-containing intervention (neoadjuvant chemotherapy) and reports clinical outcomes, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as a primary or key secondary outcome; the primary outcome is tumor immune response (TILs), and clinical outcomes like survival are mentioned only as exploratory without formal analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer. PMID 40488858 · Eur J Nucl Med Mol Imaging · 2025-Dec The study is a phase 3 randomized trial in human oncology with a drug intervention and reports original results, but it is not randomized (self-controlled design) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. PMID 40488446 · Eur J Heart Fail · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration. PMID 40466770 · Ophthalmol Retina · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience. PMID 40445123 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis. PMID 40420438 · Arthritis Rheumatol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. PMID 40417858 · Arthritis Rheumatol · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia. PMID 40417835 · J Med Econ · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial. PMID 40376714 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder. PMID 40331914 · Eur J Psychotraumatol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. PMID 40325343 · Transl Stroke Res · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis. PMID 40288918 · Eur Urol Oncol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study. PMID 40195167 · Expert Rev Vaccines · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers. PMID 40174609 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis. PMID 40122140 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise on inflammation, circulating tumor cells, and circulating tumor DNA in colorectal cancer. PMID 40107449 · J Sport Health Sci · 2025-Dec The study is a randomized trial in oncology (colorectal cancer) but is ineligible because it lacks a drug intervention (exercise-only) and does not report a primary or key secondary time-to-event efficacy endpoint. The endpoints are biomarker changes. The trial phase is also not definitively established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages. PMID 39998495 · Emerg Microbes Infect · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719). PMID 39972049 · Prostate Cancer Prostatic Dis · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China. PMID 39916494 · Expert Rev Vaccines · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial. PMID 39900352 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China. PMID 39895085 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. PMID 39894454 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. PMID 39868766 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies. PMID 39840832 · Hum Vaccin Immunother · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents. PMID 39836458 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials. PMID 39799945 · J Dermatolog Treat · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. PMID 39761965 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. PMID 39720838 · Expert Rev Vaccines · 2025-Dec 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of a combined exercise and dietary intervention on clinical outcomes in patients with ovarian cancer: the Physical Activity and Dietary intervention in OVArian cancer (PADOVA) randomized controlled trial. PMID 39244208 · Int J Gynecol Cancer · 2025-Dec The record describes a Phase II randomized controlled trial (PADOVA trial, NTR6300) evaluating an exercise/dietary intervention alongside standard chemotherapy in ovarian cancer. While it is oncologic, human, randomized, includes a drug intervention, and reports time-to-event data (PFS with HR), it does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III trial. The abstract does not state the phase, and the trial registration NTR6300 is for a Phase II study. Furthermore, the primary endpoint of the trial is relative dose intensity (a treatment adherence measure), and PFS is a secondary outcome. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results. PMID 38702555 · J Cancer Surviv · 2025-Dec This is a pilot randomized trial (Phase I/II equivalent) of a psychosocial intervention to improve adherence to adjuvant endocrine therapy in breast cancer. While it involves a drug therapy context, the study is not a definitive Phase III/IIIb trial, and the primary outcome is adherence intention (a psychosocial/behavioral endpoint), not a clinical time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Low Social Well-Being in Advanced and Metastatic Prostate Cancer: Effects of a Randomized Controlled Trial of Cognitive Behavioral Stress Management. PMID 38378974 · Int J Behav Med · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Short-course hypofractionated radiotherapy of 4 Gy per fraction for limited-stage small cell lung cancer: a randomized pilot trial. PMID 40948832 · Transl Lung Cancer Res · 2025-Aug-31 The record is an oncology randomized pilot trial with human patients and time-to-event efficacy endpoints, but it is excluded because the intervention is radiotherapy-only (no drug-containing arm) and the phase/definitive nature is not established as Phase II/III or Phase III/IIIb. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme. PMID 40889900 · BMJ Open Gastroenterol · 2025-Aug-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes. PMID 40887579 · Cardiovasc Diabetol · 2025-Aug-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study). PMID 40887121 · BMJ Open · 2025-Aug-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. PMID 40950337 · J Gastrointest Oncol · 2025-Aug-30 This is a retrospective cohort study, not a randomized controlled trial. It does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay. PMID 40886427 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age. PMID 40763490 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study. PMID 40752250 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine. PMID 40749348 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。 |
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older. PMID 40714528 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial. PMID 40714527 · Vaccine · 2025-Aug-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial. PMID 40966617 · Age Ageing · 2025-Aug-29 The study is a randomized, placebo-controlled trial of a cocoa extract supplement, but it is not an oncology study. It focuses on inflammaging biomarkers in older adults, not on cancer outcomes. The primary endpoints are changes in biomarkers (hsCRP, IFN-γ, etc.), not time-to-event efficacy endpoints such as OS, PFS, or DFS. Therefore, it does not meet the eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Four-week remotely supervised aerobic exercise during the COVID-19 era: Exploring physical performance and psychosocial health in adults without COVID-19 living in rural settings. PMID 40898552 · Medicine (Baltimore) · 2025-Aug-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Integrated Model of Cancer Control for Early Detection and Treatment in Adolescents and Young Adults Living With HIV: Protocol for a Cluster Randomized Controlled Trial. PMID 40882199 · JMIR Res Protoc · 2025-Aug-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |